Bayer AG CFO Wolfgang Nickl – Monsanto litigations, the pharma pipeline, and Dynamic Shared Ownership

Bayer AG is one of the most important German companies in the life science business. Now the organization is at a historic turning point, dealing with numerous lawsuits resulting from the acquisition of Monsanto, a pharmaceutical pipeline that is losing exclusivity, and a significant decline in market value over the past few years. This has also sparked investor discussions about the possibility of splitting up the company. In this episode, CFO Wolfgang Nickl will discuss how he, along with the new CEO Bill Anderson and the rest of the Bayer team, are facing these challenges. Join us for an interesting discussion on what lies ahead for Bayer and how the company will transform in the coming years. Guest: Wolfgang Nickl Hosts: Martin Glaum & Gori von Hirschhausen Editorial Team: Simon Görlach & Marvin Schöne